// App-Quantinova.ai

e15210 : Oral low-dose cyclophosphamide, as a second-line agent, in patients with primary docetaxel refractory metastatic castration-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Daniela Shapiro

Principal Investigators

  • James Thomas Symanowski

  • Nicholas J. Vogelzang

  • Oscar B. Goodman

Medical Centers

  • Comprehensive Cancer Centers of Nevada, The US Oncology Network, Las Vegas, NV

  • Nevada Cancer Institute, Las Vegas, NV

  • Nevada Cancer Institute Medical Group, Las Vegas, NV

  • Nevada Cancer Institute/University of Nevada School of Medicine, Las Vegas, NV

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

  • Prostate specific antigen

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved